These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 26249841)

  • 21. The beneficial effect of metformin on β-cell function in non-obese Chinese subjects with newly diagnosed type 2 diabetes.
    Bi Y; Tong GY; Yang HJ; Cai MY; Ma JH; Liang J; Xin B; Miao H; Peng ZH; Zhu DL
    Diabetes Metab Res Rev; 2013 Nov; 29(8):664-72. PubMed ID: 23955995
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Retrospective study comparing healthcare costs and utilization between commercially insured patients with type 2 diabetes mellitus who are newly initiating exenatide once weekly or liraglutide in the United States.
    Johnston SS; Nguyen H; Cappell K; Nelson JK; Chu BC; Kalsekar I
    J Med Econ; 2015; 18(9):666-77. PubMed ID: 25867133
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Co-administration of liraglutide with insulin detemir demonstrates additive pharmacodynamic effects with no pharmacokinetic interaction.
    Morrow L; Hompesch M; Guthrie H; Chang D; Chatterjee DJ
    Diabetes Obes Metab; 2011 Jan; 13(1):75-80. PubMed ID: 21114606
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Durable efficacy of liraglutide in patients with type 2 diabetes and pronounced insulin-associated weight gain: 52-week results from the Effect of Liraglutide on insulin-associated wEight GAiN in patients with Type 2 diabetes' (ELEGANT) randomized controlled trial.
    de Wit HM; Vervoort GM; Jansen HJ; de Galan BE; Tack CJ
    J Intern Med; 2016 Mar; 279(3):283-92. PubMed ID: 26553486
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Improved meal-related insulin processing contributes to the enhancement of B-cell function by the DPP-4 inhibitor vildagliptin in patients with type 2 diabetes.
    Ahrén B; Pacini G; Tura A; Foley JE; Schweizer A
    Horm Metab Res; 2007 Nov; 39(11):826-9. PubMed ID: 17992639
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Liraglutide: effects beyond glycaemic control in diabetes treatment.
    McGill JB
    Int J Clin Pract Suppl; 2010 Oct; (167):28-34. PubMed ID: 20887302
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Liraglutide, a once-daily human GLP-1 analogue, improves pancreatic B-cell function and arginine-stimulated insulin secretion during hyperglycaemia in patients with Type 2 diabetes mellitus.
    Vilsbøll T; Brock B; Perrild H; Levin K; Lervang HH; Kølendorf K; Krarup T; Schmitz O; Zdravkovic M; Le-Thi T; Madsbad S
    Diabet Med; 2008 Feb; 25(2):152-6. PubMed ID: 18201212
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Sitagliptin and pioglitazone provide complementary effects on postprandial glucose and pancreatic islet cell function.
    Alba M; Ahrén B; Inzucchi SE; Guan Y; Mallick M; Xu L; O'Neill EA; Williams-Herman DE; Kaufman KD; Goldstein BJ
    Diabetes Obes Metab; 2013 Dec; 15(12):1101-10. PubMed ID: 23782502
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Three years of liraglutide treatment offers continuously optimal glycemic control in a pediatric patient with maturity-onset diabetes of the young type 3.
    Urakami T; Habu M; Okuno M; Suzuki J; Takahashi S; Yorifuji T
    J Pediatr Endocrinol Metab; 2015 Mar; 28(3-4):327-31. PubMed ID: 25332292
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The effects of glucagon-like peptide-1 on the beta cell.
    Vilsbøll T
    Diabetes Obes Metab; 2009 Dec; 11 Suppl 3():11-8. PubMed ID: 19878257
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Assessment of beta-cell function in young patients with type 2 diabetes: arginine-stimulated insulin secretion may reflect beta-cell reserve.
    Sjostrand M; Carlson K; Arnqvist HJ; Gudbjörnsdottir S; Landin-Olsson M; Lindmark S; Nyström L; Svensson MK; Eriksson JW; Bolinder J
    J Intern Med; 2014 Jan; 275(1):39-48. PubMed ID: 24482829
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The utility of assessing C-peptide in patients with insulin-treated type 2 diabetes: a cross-sectional study.
    Dario T; Riccardo G; Silvia P; Mikiko W; Daria M; Andrea P; Giuseppe D; Elvira F; Paolo P; Silvia M
    Acta Diabetol; 2021 Apr; 58(4):411-417. PubMed ID: 33185778
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Glucagon stimulation test as a possible predictor of residual β-cell function.
    Yoshida K; Urakami T; Morioka I
    Pediatr Int; 2021 May; 63(5):536-542. PubMed ID: 32894600
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Postprandial serum C-peptide to plasma glucose ratio as a predictor of subsequent insulin treatment in patients with type 2 diabetes.
    Saisho Y; Kou K; Tanaka K; Abe T; Kurosawa H; Shimada A; Meguro S; Kawai T; Itoh H
    Endocr J; 2011; 58(4):315-22. PubMed ID: 21415555
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Liraglutide Compromises Pancreatic β Cell Function in a Humanized Mouse Model.
    Abdulreda MH; Rodriguez-Diaz R; Caicedo A; Berggren PO
    Cell Metab; 2016 Mar; 23(3):541-6. PubMed ID: 26876561
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Association between beta cell function and future glycemic control in patients with type 2 diabetes.
    Saisho Y; Kou K; Tanaka K; Abe T; Shimada A; Kawai T; Itoh H
    Endocr J; 2013; 60(4):517-23. PubMed ID: 23268927
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comment on Retnakaran et al. Liraglutide and the preservation of pancreatic β-cell function in early type 2 diabetes: the LIBRA trial. Diabetes Care 2014;37:3270-3278.
    Arnolds S; Sawicki PT
    Diabetes Care; 2015 Feb; 38(2):e25. PubMed ID: 25614698
    [No Abstract]   [Full Text] [Related]  

  • 38. Response to Comment on Retnakaran et al. Liraglutide and the preservation of pancreatic β-cell function in early type 2 diabetes: the LIBRA trial. Diabetes Care 2014;37:3270-3278.
    Retnakaran R; Kramer CK; Zinman B
    Diabetes Care; 2015 Feb; 38(2):e26. PubMed ID: 25614699
    [No Abstract]   [Full Text] [Related]  

  • 39. Effects of liraglutide on intrapancreatic fat deposition in patients with type 2 diabetes.
    Kuriyama T; Ishibashi C; Kozawa J; Baden MY; Horii T; Niki A; Ozawa H; Hosokawa Y; Fujita Y; Sadahiro K; Satoh T; Hamaguchi T; Shimomura I
    Clin Nutr ESPEN; 2024 Feb; 59():208-213. PubMed ID: 38220377
    [TBL] [Abstract][Full Text] [Related]  

  • 40. C-Peptide Area Under the Curve at Glucagon Stimulation Test Predicts Glucose Improvements by GLP-1 Receptor Analogue: A Retrospective Observational Study.
    Ohbatake A; Yagi K; Karashima S; Shima Y; Miyamoto Y; Asaka H; Okazaki S; Kometani M; Kawashiri MA; Takeda Y; Yoneda T; Chujo D
    Diabetes Ther; 2019 Apr; 10(2):673-681. PubMed ID: 30788807
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.